Magnesium Chloride

證據等級: L5

預測適應症: 10 個

Magnesium Chloride: From Electrolyte Replacement to Congestive Heart Failure

One-Sentence Summary

Magnesium chloride (MgCl₂) is an inorganic salt used clinically as an electrolyte replacement agent to correct hypomagnesaemia, a condition frequently arising in patients on long-term diuretic therapy. The TxGNN model predicts it may be effective for congestive heart failure (CHF), supported by a mechanistically compelling rationale: CHF patients are prone to diuretic-induced magnesium wasting, and MgCl₂ oral supplementation has been shown to reduce arrhythmia risk and improve myocardial function. Current evidence includes 1 directly relevant small clinical trial (PMID 8237806) and multiple observational and review publications, placing overall support at Evidence Level L3.

Quick Overview

Item	Content
Original Indication	Electrolyte replacement / correction of hypomagnesaemia (no formal Singapore registration)
Predicted New Indication	Congestive Heart Failure
TxGNN Prediction Score	97.07%
Evidence Level	L3
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Magnesium is the second most abundant intracellular cation and plays a critical role in cardiac electrophysiology. It stabilises cell membrane potential, regulates the Na⁺/K⁺-ATPase pump, and acts as a physiological antagonist to voltage-gated calcium channels. In cardiomyocytes, adequate Mg²⁺ is essential for normal action potential duration and prevention of triggered arrhythmias such as torsades de pointes.

In congestive heart failure, the use of loop diuretics (e.g. furosemide) and thiazides is the standard of care for decongestion. However, these agents promote urinary wasting of magnesium alongside potassium and sodium. The resulting hypomagnesaemia significantly increases susceptibility to ventricular ectopy, Q-T prolongation, and sudden cardiac death — complications that contribute substantially to the high CHF mortality burden. Animal studies further confirm that dietary magnesium deficiency alone can induce a reversible, metabolic diastolic cardiomyopathy (PMID 34096318).

Magnesium chloride, as the most bioavailable oral magnesium salt, is well-positioned to correct this deficiency. A landmark randomised crossover trial (PMID 8237806) directly studied long-term oral MgCl₂ replacement in 21 CHF patients on loop diuretics, demonstrating restoration of serum and tissue magnesium levels and associated antiarrhythmic benefits. Combined with its synergistic effect on potassium repletion (refractory hypokalaemia often resolves only after magnesium correction), the mechanistic case for MgCl₂ supplementation in CHF is biologically plausible and clinically grounded.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03980574	N/A	Completed	10	Pilot crossover study of dietary supplementation (potentially including magnesium) in CHF patients with and without diabetes; assessed 6-minute walk distance and readmission rates
NCT03439514	Phase 3	Terminated	77	Dilated cardiomyopathy (LMNA mutation) treated with p38α MAPK inhibitor ARRY-371797; indication relevant but intervention unrelated to MgCl₂
NCT02560519	Phase 4	Completed	1,386	Albumin vs Ringer's lactate (containing Mg²⁺) in cardiac surgery; large study exploring electrolyte-containing crystalloids, though primary endpoint was colloid selection
NCT04393493	Phase 2	Completed	80	Two furosemide strategies in type 1 cardiorenal syndrome; relevant to diuretic-electrolyte context in CHF
NCT03031496	Phase 1	Completed	42	Bioequivalence study of hydrochlorothiazide/amiloride for CHF, hypertension, and cirrhosis with ascites; electrolyte-sparing diuretic context relevant
NCT07163936	N/A	Not Yet Recruiting	80	Citrate-based dialysate with added magnesium to prevent vascular calcification in CKD; directly tests Mg²⁺ supplementation in a related cardiovascular-renal population
NCT06021860	Phase 4	Unknown	96	Spironolactone oral suspension PK/PD in paediatric oedema due to heart failure or cirrhosis; electrolyte management context

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8237806	1993	Controlled Trial (RCT crossover)	Am J Cardiology	Long-term oral MgCl₂ replacement in 21 CHF patients on loop diuretics restored serum Mg and reduced arrhythmia susceptibility; only direct trial of oral MgCl₂ in CHF
2755214	1989	Controlled Trial	Magnesium	K⁺ alone vs K⁺+Mg combination in CHF on hydrochlorothiazide; demonstrated that combined K⁺-Mg supplementation more effectively corrected hypokalaemia
40530753	2025	Review	Eur J Heart Failure	Comprehensive review of water and electrolyte homeostasis during decongestion in CHF; highlights that Mg²⁺/K⁺ co-depletion is a key consequence of loop diuretic use
8861138	1995	Critical Review	Magnesium Research	Antiarrhythmic actions of magnesium in CHF; epidemiological evidence for Mg deficit in sudden cardiac death, enzymatic roles in myocyte function
34096318	2021	Preclinical Study	J Am Heart Assoc	Low-Mg diet in C57BL/6J mice produced reversible diastolic cardiomyopathy; fully reversed upon Mg repletion — establishes direct causal link between Mg deficiency and cardiac dysfunction
2650515	1989	Review	Am J Cardiology	Cardiovascular consequences of Mg deficiency: arterial/myocardial lesions, atherogenesis, thrombogenesis; Mg and Cl⁻ loss complicates K⁺ repletion
4091044	1985	Observational	Acta Med Scandinavica	108 CHF/hypertension patients on long-term diuretics showed consistent Mg and K⁺ depletion in skeletal muscle even with normal serum levels
2309624	1990	Review	Am J Cardiology	Diuretic-electrolyte interaction in CHF; kaliuresis worsens with continued therapy, Mg depletion underlies refractory hypokalaemia
25660927	2015	Review	J Am Coll Cardiology	Depletional hyponatraemia in acute decompensated CHF driven by diuretics; Mg/K supplementation recommended when plasma levels are low
2436474	1987	Review	Am J Medicine	Potassium and magnesium depletion from diuretic therapy; serum levels can appear normal despite significant tissue depletion, underscoring need for empirical supplementation

Singapore Market Information

Magnesium chloride (DB09407) currently has no registered products with the Health Sciences Authority (HSA) in Singapore. The drug is not approved or commercially marketed in Singapore under any dosage form or indication.

There are no authorization records to display.

Safety Considerations

Please refer to the package insert for safety information. No Singapore HSA-specific warnings, contraindications, or drug interaction data were retrievable for this submission. Clinicians should consult the relevant product monograph and standard pharmacology references before use.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic and epidemiological case for magnesium chloride in congestive heart failure is strong — diuretic-induced hypomagnesaemia is well-documented, MgCl₂ oral replacement has been directly studied in CHF in a small RCT (PMID 8237806) with positive signals, and animal data confirm that Mg deficiency alone can cause reversible cardiomyopathy. However, evidence remains at Level L3 (observational and small controlled studies), with no large-scale Phase 2/3 RCT specifically evaluating oral MgCl₂ supplementation as an adjunct in CHF management.

To proceed, the following is needed:

Safety data retrieval: Obtain and review the MgCl₂ product monograph / prescribing information to confirm contraindications (e.g. renal impairment, hypermagnesaemia) and drug interactions (e.g. with digoxin, aminoglycosides)
Singapore regulatory pathway: Determine if MgCl₂ oral formulation can be registered as a supplement or prescription product via HSA; assess GMP-compliant supply chain
Dose-finding clarification: The 1993 trial (PMID 8237806) used oral MgCl₂ at a specific replacement dose — confirm optimal dosing, frequency, and target serum Mg levels for CHF
Renal function gating: Mg supplementation is contraindicated in significant renal impairment (eGFR < 30 mL/min typically); a patient selection framework is required
Larger prospective study: Design a Phase 2 RCT evaluating oral MgCl₂ supplementation (vs placebo) in CHF patients on loop diuretics, with endpoints of serum Mg normalisation, arrhythmia burden (24-hour Holter), hospitalisation rates, and NYHA class
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.